drugset / Trial / NCT00911157
The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the efficacy (as measured by the rate of recurrent symptomatic Venous Thromboembolism \[VTE\] (i.e., Pulmonary thromboembolism \[PE\] and Deep Vein Thrombosis \[DVT\])) and safety of GSK576428 as the initial treatment in subjects with acute symptomatic DVT in an open-label design.
Timeline
- Start
- 2008-06
- Primary completion
- 2009-11
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fondaparinux | Other / unclassified | 5 mg | Subcutaneous |
| Subject | Fondaparinux | Other / unclassified | 7.5 mg | Subcutaneous |
| Subject | Fondaparinux | Other / unclassified | 10 mg | Subcutaneous |
| Subject | Heparin | Other / unclassified | — | — |